- Home
- QS vs XENE Comparison
QS vs XENE Comparison
Compare QS & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QS
- XENE
- Stock Information
- Founded
- QS 2010
- XENE 1996
- Country
- QS United States
- XENE Canada
- Employees
- QS N/A
- XENE N/A
- Industry
- QS Auto Parts:O.E.M.
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- QS Consumer Discretionary
- XENE Health Care
- Exchange
- QS Nasdaq
- XENE Nasdaq
- Market Cap
- QS 2.7B
- XENE 3.0B
- IPO Year
- QS N/A
- XENE 2014
- Fundamental
- Price
- QS $4.74
- XENE $39.83
- Analyst Decision
- QS Hold
- XENE Strong Buy
- Analyst Count
- QS 5
- XENE 10
- Target Price
- QS $6.14
- XENE $57.30
- AVG Volume (30 Days)
- QS 14.4M
- XENE 382.6K
- Earning Date
- QS 10-23-2024
- XENE 11-12-2024
- Dividend Yield
- QS N/A
- XENE N/A
- EPS Growth
- QS N/A
- XENE N/A
- EPS
- QS N/A
- XENE N/A
- Revenue
- QS N/A
- XENE N/A
- Revenue This Year
- QS N/A
- XENE N/A
- Revenue Next Year
- QS N/A
- XENE $1,600.08
- P/E Ratio
- QS N/A
- XENE N/A
- Revenue Growth
- QS N/A
- XENE N/A
- 52 Week Low
- QS $4.67
- XENE $28.20
- 52 Week High
- QS $10.03
- XENE $50.99
- Technical
- Relative Strength Index (RSI)
- QS 36.55
- XENE 39.07
- Support Level
- QS $4.80
- XENE $41.42
- Resistance Level
- QS $5.17
- XENE $44.61
- Average True Range (ATR)
- QS 0.22
- XENE 1.53
- MACD
- QS -0.04
- XENE -0.36
- Stochastic Oscillator
- QS 1.65
- XENE 2.99
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed an anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.